Gerresheimer is to invest in the rapid expansion of its manufacturing, supply and logistics capability for glass vials in the US.

The investment will expand Gerresheimer’s capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging.

As part of the project, the existing facility in North Carolina will be enlarged by the installation of new modernised vial forming lines and a new warehouse.

As the investment will lead to an increase in the number of people employed, new offices will also be part of the expansion plan.

The project is supported by the Biomedical Advanced Research and Development Authority (BARDA)* office in a 70/30 cost-share co-operative agreement. The office has agreed to provide up to approx. $66 million to Gerresheimer for the project.

Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with interchangeable Type 1 vials (glass borosilicate and/or aluminosilicate) and Gx Elite Glass Vials capability.

The vials can be used in vaccination campaigns against infectious diseases, such as COVID-19 and others.

Dietmar Siemssen, CEO of Gerresheimer, said: "Gerresheimer is honoured to support the US government in strengthening its pharmaceutical supply chain for current and future healthcare emergencies. The agreement confirms our role as a supplier of system critical products, such as pharmaceutical primary packaging solutions and drug delivery systems for the healthcare sector.”

The company is committed to sourcing most of its raw materials from US domestic suppliers to enhance the levels of responsiveness, dependability, quality and domestic supply chain integration.

Gerresheimer is furthermore incorporating sustainable design principles to implement energy efficiency measures, comply with storm water management requirements and reduce waste for the upgrades and expansion.

*BARDA is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS).